{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T01:57:58Z","timestamp":1772071078809,"version":"3.50.1"},"reference-count":22,"publisher":"Hindawi Limited","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1834,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1111\/j.1365-2710.2010.01172.x","type":"journal-article","created":{"date-parts":[[2010,8,29]],"date-time":"2010-08-29T17:12:00Z","timestamp":1283101920000},"page":"128-134","source":"Crossref","is-referenced-by-count":31,"title":["The repositioning of the anti-fungal agent ciclopirox olamine as a novel therapeutic agent for the treatment of haematologic malignancy"],"prefix":"10.1155","volume":"36","author":[{"given":"S. J.","family":"Weir","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Patton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Castle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Rajewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Kasper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. D.","family":"Schimmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","published-online":{"date-parts":[[2010,8,24]]},"reference":[{"key":"10.1111\/j.1365-2710.2010.01172.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1365-2133.1976.tb15537.x","article-title":"Ciclopirox: a new topical pyrodonium antimycotic agent. A double-blind study in superficial dermatomycoses","volume":"95","author":"Sehgal","year":"1976","journal-title":"British Journal of Dermatology"},{"key":"10.1111\/j.1365-2710.2010.01172.x-BIB2|cit2","first-page":"273","article-title":"Antimicrobial activity of iodoquinol 1%-hydrocortisone acetate 2% gel against ciclopirox and clotrimazole","volume":"82","author":"Burnett","year":"2008","journal-title":"Cutis"},{"key":"10.1111\/j.1365-2710.2010.01172.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1159\/000068904","article-title":"Randomized, open-labeled, non-inferiority study between ciclopiroxolamine 1% cream and ketoconazole 2% foaming gel in mild to moderate facial seborrheic dermatitis","volume":"206","author":"Chosidow","year":"2003","journal-title":"Dermatology"},{"key":"10.1111\/j.1365-2710.2010.01172.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1046\/j.1365-2133.2001.04194.x","article-title":"Randomized, placebo-controlled, double-blind study on clinical efficacy of ciclopiroxolamine 1% cream in facial seborrhoeic dermatitis","volume":"144","author":"Dupuy","year":"2001","journal-title":"British Journal Dermatology"},{"key":"10.1111\/j.1365-2710.2010.01172.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/095466302317584395","article-title":"A randomised, single-blind, single-centre clinical trial to evaluate comparative clinical efficacy of shampoos containing ciclopirox olamine (1.5%) and salicylic acid (3%), or ketoconazole (2%, Nizoral) for the treatment of dandruff\/seborrhoeic dermatitis","volume":"13","author":"Squire","year":"2002","journal-title":"Journal of Dermatology Treatment"},{"key":"10.1111\/j.1365-2710.2010.01172.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1080\/09546630500420183","article-title":"Combination of oral terbinafine and topical ciclopirox compared to oral terbinafine for the treatment of onychomycosis","volume":"16","author":"Avner","year":"2005","journal-title":"Journal of Dermatology Treatment"},{"key":"10.1111\/j.1365-2710.2010.01172.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1182\/blood-2005-03-037648","article-title":"Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL-positive leukemias identified by a proteomics approach","volume":"109","author":"Balabanov","year":"2007","journal-title":"Blood"},{"key":"10.1111\/j.1365-2710.2010.01172.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2009-03-209965","article-title":"Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells","volume":"114","author":"Eberhard","year":"2009","journal-title":"Blood"},{"key":"10.1111\/j.1365-2710.2010.01172.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1126\/science.1139851","article-title":"Modeling the initiation and progression of human acute leukemia in mice","volume":"316","author":"Barabe","year":"2007","journal-title":"Science"},{"key":"10.1111\/j.1365-2710.2010.01172.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1038\/sj.leu.2403917","article-title":"Direct evidence for cooperating genetic events in the leukemic transformation of normal human hematopoietic cells","volume":"19","author":"Warner","year":"2005","journal-title":"Leukemia"},{"key":"10.1111\/j.1365-2710.2010.01172.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/ijc.10515","article-title":"The antifungal drug ciclopirox inhibits deoxyhypusine and proline hydroxylation, endothelial cell growth and angiogenesis in vitro","volume":"100","author":"Clement","year":"2002","journal-title":"International Journal of Cancer"},{"key":"10.1111\/j.1365-2710.2010.01172.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1096\/fj.02-0586fje","article-title":"The antimycotic ciclopirox olamine induces HIF-1alpha stability, VEGF expression, and angiogenesis","volume":"17","author":"Linden","year":"2003","journal-title":"FASEB Journal"},{"key":"10.1111\/j.1365-2710.2010.01172.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1158\/1535-7163.MCT-05-0384","article-title":"A Ferrous-Triapine complex mediates formation of reactive oxygen species that inactivate human ribonucleotide reductase","volume":"5","author":"Shao","year":"2006","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1111\/j.1365-2710.2010.01172.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s10637-008-9123-6","article-title":"A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas","volume":"26","author":"Attia","year":"2008","journal-title":"Investigational New Drugs"},{"key":"10.1111\/j.1365-2710.2010.01172.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s10637-008-9115-6","article-title":"Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia","volume":"26","author":"Odenike","year":"2008","journal-title":"Investigational New Drugs"},{"key":"10.1111\/j.1365-2710.2010.01172.x-BIB16|cit16","first-page":"1337","article-title":"[Investigations on the pharmacokinetics and biotransformation of the antimycotic drug ciclopiroxolamine in animals and man after topical and systemic application]","volume":"31","author":"Kellner","year":"1981","journal-title":"Arzneimittel-Forschung"},{"key":"10.1111\/j.1365-2710.2010.01172.x-BIB17|cit17","unstructured":""},{"key":"10.1111\/j.1365-2710.2010.01172.x-BIB18|cit18","first-page":"1360","article-title":"[Clinical results with the antimycotic agent ciclopiroxolamine (author\u2019s transl)]","volume":"31","author":"Adam","year":"1981","journal-title":"Arzneimittel-Forschung"},{"key":"10.1111\/j.1365-2710.2010.01172.x-BIB19|cit19","first-page":"1328","article-title":"[Studies on the pharmacology and toxicology of ciclopiroxolamine (author\u2019s transl)]","volume":"31","author":"Alpermann","year":"1981","journal-title":"Arzneimittel-Forschung"},{"key":"10.1111\/j.1365-2710.2010.01172.x-BIB20|cit20","unstructured":""},{"key":"10.1111\/j.1365-2710.2010.01172.x-BIB21|cit21","unstructured":""},{"key":"10.1111\/j.1365-2710.2010.01172.x-BIB22|cit22","unstructured":""}],"container-title":["Journal of Clinical Pharmacy and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2710.2010.01172.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2710.2010.01172.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T18:03:41Z","timestamp":1671818621000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2710.2010.01172.x"}},"subtitle":["Ciclopirox olamine for haematologic malignancy"],"short-title":[],"issued":{"date-parts":[[2010,8,24]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,4]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2710.2010.01172.x","relation":{},"ISSN":["0269-4727"],"issn-type":[{"value":"0269-4727","type":"print"}],"subject":[],"published":{"date-parts":[[2010,8,24]]}}}